3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 10 areas
0
News (30d)
Quiet
Mundipharma Research Limited is a company with 3 orphan drug designations across 5 rare diseases. gene therapy candidates in 1 disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| T-cell non-Hodgkin lymphoma | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride | Des.TrialAppr. |
| acute lymphoblastic leukemia | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride | Des.TrialAppr. |
| ataxia telangiectasia | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride | Des.TrialAppr. |
| chronic lymphocytic leukemia/small lymphocytic lymphoma | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride | Des.TrialAppr. |
| chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride | Des.TrialAppr. |
50% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
1/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
50% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
1/5
candidate diseases
0
avg importance: 0
0
affecting portfolio